CPX-351 (Liposomal Cytarabine dan Daunorubicin) versus venetoclax ditambah terapi agen hipometilasi pada leukemia myeloid akut yang baru didiagnosis: perbandingan retrospektif yang melibatkan 600 pasien Mayo Clinic | Jurnal Kanker Darah – Nature
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving…
Isi lengkap artikel
The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (N = 277,46%), post-myelodysplastic syndrome (post-MDS, N = 114,19%), post-myeloproliferative neoplasm (post-MPN, N = 70,12%), post-MDS/MPN (N = 36,6%), and t-AML (N = 103,17%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p
Produk Terkait Artikel Ini
Produk ini dicocokkan otomatis berdasarkan judul, ringkasan, dan isi artikel.
Pertanyaan Umum
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Venetoclax – Beli online VECLADX Venetoclax 100mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.